(Pro)renin receptor: a treatment target for diabetic retinopathy?
Wilkinson-Berka
Jennifer L
JL
Department of Immunology, Monash University, Prahran, Victoria, Australia. jennifer.wilkinson-berka@med.monash.edu.au
Campbell
Duncan J
DJ
D047228:Angiotensin II Type 1 Receptor Blockers / Q000037:antagonists & inhibitors*; D000818:Animals; D003924:Diabetes Mellitus, Type 2 / Q000150:complications; D003930:Diabetic Retinopathy / Q000188:drug therapy* / Q000503:physiopathology*; D007606:Juxtaglomerular Apparatus / Q000503:physiopathology; D009389:Neovascularization, Pathologic / Q000503:physiopathology; D009457:Neuroglia / Q000502:physiology; D009474:Neurons / Q000502:physiology; D051381:Rats; D011956:Receptors, Cell Surface / Q000502:physiology*; D012083:Renin / Q000502:physiology*; D012084:Renin-Angiotensin System / Q000502:physiology*; D012165:Retinal Ganglion Cells / Q000502:physiology; D025262:Vacuolar Proton-Translocating ATPases / Q000502:physiology*; D014822:Vitreous Body / Q000503:physiopathology; D000093342:Prorenin Receptor
D047228:Angiotensin II Type 1 Receptor Blockers; D011956:Receptors, Cell Surface; D012083:Renin; D025262:Vacuolar Proton-Translocating ATPases; C458319:ATP6AP2 protein, human; D000093342:Prorenin Receptor